NCT06764251尚未招募2 期
A Single-centre Phase II Clinical Study of Tislelizumab Combined with SOX Regimen in the Treatment of Locally Advanced Gastric Cancer/gastroesophageal Junction Adenocarcinoma
Liaoning Cancer Hospital & Institute0 个研究点目标入组 20 人开始时间: 2024年12月30日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 20
- 主要终点
- Pathologic complete response rate (pCR)
研究概览
简要总结
This study is to evaluate the efficacy of neoadjuvant long-term treatment with tislelizumab in combination with SOX in the treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Willing to participate in this study, able to sign the informed consent form, and with compliance;
- •No gender restriction, aged ≥18 and ≤70 years (at the time of signing the informed consent form);
- •ECO score of 0-1;
- •Estimated survival ≥6 months;
- •HER-2 negative;
- •Central laboratory confirmed PD-L1 expression in the, with a combined positive score (CPS) ≥1;
- •Histological and radiological assessment confirmed as advanced gastric cancer (GC) or gastroesal junction (GEJ) adenocarcinoma, with a clinical stage of cT3-T4aN M0;
- •Pre-enrollment by the attending physician to determine eligibility for R0 resection with curative intent;
- •Good cardiac function. Patients with underlying ischemic, valvular disease, or other severe heart disease should have a preoperative assessment by a cardiologist if there are clinical indications;
- •No prior cytotoxic or targeted, no prior partial or complete esophagogastric tumor resection;
- •Negative for hepatitis B surface antigen (HBsAg) and hepatitis core antibody (HBcAb). If HBsAg is positive or HBcAb is positive, then the hepatitis B virus deoxyribonucleic acidHBV-DNA) must be <1000 copies/mL or <200 IU/mL or <the upper limit of normal (ULN) at research center to be eligible;
- •Negative for hepatitis C virus (HCV) antibody;
- •Normal major organ function, as defined by the criteria (within 14 days before the first dose, without transfusions, albumin, recombinant human thrombopoietin, or colony-stulating factor (CSF) treatment): Blood routine examination: Hemoglobin (Hb) ≥90g/L; absolute neutrophil count (ANC ≥1.5×109/L; platelets (PLT) ≥80×109/L; Biochemical examination: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN (≤5×ULN liver metastasis); total bilirubin (TBIL) ≤1.5×ULN (≤3×ULN for Gilbert's syndrome); seruminine (Cr) ≤1.5×ULN, or creatinine clearance rate ≥60mL/min; Coagulation function: Activated partialboplastin time (APTT), international normalized ratio (INR), and prothrombin time (PT) ≤1.5×ULN; Dpler ultrasound assessment: Left ventricular ejection fraction (LVEF) ≥50%; Normal thyroid function, defined as thyroid-stimulating hormone (T) within the normal range. If baseline TSH is out of range, patients with total T3 (or FT3) and FT4 within the normal range also be included; Clinical judgment by the doctor that organ function is sufficient.
- •Fertile subjects must use appropriate contraception during the study and for 20 days after the study ends, have a negative serum pregnancy test within 7 days before enrollment, and must not be breastfeeding
排除标准
- •Have had or simultaneously have other active malignant tumors within 5 years. Cured localized tumors, as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, prostate carcinoma in situ, cervical carcinoma in situ, and breast in situ, are eligible;
- •Patients who are preparing for or have previously undergone organ or bone marrow transplantation;
- •Have ≥2 grade myocardial ischem or myocardial infarction, arrhythmia (QTc ≥470ms), and ≥2 grade congestive heart failure (New York Heart AssociationNYHA] classification);
- •Human immunodeficiency virus (HIV) infection;
- •Have active pulmonary tuberculosis;
- •Have a history or current presence interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, severe pulmonary dysfunction, etc., which may interfere with the detection and management of suspected drug-related pulmonary toxicity;
- •Have known active or suspected autoimmune diseases, except those in a stable state at the time of enrollment (not requiring systemic immunospressive therapy);
- •Have received live vaccine treatment within 28 days before the first dose; seasonal flu vaccines are not included;
- •Have received or need receive systemic corticosteroids (> 10 mg/day prednisone equivalent dose) or other immunosuppressive drugs within 14 days before the dose or during the study. However, the following cases are allowed: patients with no active autoimmune diseases can use topical or inhaled corticosteroids, or hormone replacement therapy with a dose ≤ 10 mg/day prednisone equivalent dose;
- •Have any active infection that requires systemic anti-infective within 14 days before the first dose; prophylactic antibiotic treatment (e.g., for urinary tract infections or chronic obstructive pulmonary disease) is not;
- •Have previously received other antibodies/drugs targeting immune checkpoints, such as PD-1, PD-L1, CTLA4, etc.;
- •Are currently receiving other clinical study treatments, or the time between the end of the previous clinical study treatment and the planned start of this study treatment is less than14 days;
- •Have a known severe allergic history to any monoclonal antibody or excipients of the study drug;
- •Have a history of psychiatric drug abuse or drug addiction; patients who have stopped drinking alcohol can be enrolled; According to the investigator's judgment, patients with serious concomitant that endanger the safety of the subjects or affect the completion of the study, or patients who are deemed unsuitable for enrollment for other reasons
研究组 & 干预措施
Tislelizumab + SOX
Experimental
干预措施: Tislelizumab + SOX (Drug)
结局指标
主要结局
Pathologic complete response rate (pCR)
时间窗: 3 week
次要结局
- The R0 resection rate after radical operation(1 year)
- Major Pathological response (MPR) after radical operation(From baseline to after radical operation)
- Event Free Survival Rate from baseline to 1 year(from baseline to 1 year)
- Overall Survival rate from baseline to 1 year(From baseline to 1 year)
- Disease-related treatment failure rate from baseline to 1 year(From baseline to 1 year)
- Objective response rate from baseline to 1 year(From baseline to 1 year)
- Disease control rate from baseline to 1year(From baseline to 1year)
- Correlation between PD-L1 expression, TMB level and T cell subsets in tumour tissue samples and efficacy.(6 week)
- The safety from baseline to 1year(From baseline to 1year)
研究者
Zheng Zhichao
Offices Director
Liaoning Cancer Hospital & Institute
相似试验
尚未招募
2 期
Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA/N2 Non-small Cell Lung CancerNSCLC, Stage IIIANSCLC (non-small Cell Lung Cancer)NCT06614231Sun Yat-sen University48
已完成
2 期
Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal CancerColorectal CancerNCT05116085BeiGene33
进行中（未招募）
不适用
Tislelizumab Combined With Chemotherapy in First-line Treatment of AGCTislelizumabChemotherapyFirst-lineGastric Cancer Stage IVNCT06034964Cancer Institute and Hospital, Chinese Academy of Medical Sciences60
进行中（未招募）
2 期
Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder CarcinomaMuscle Invasive Bladder CancerUrothelial CarcinomaNCT04730219Tianjin Medical University Second Hospital48
招募中
2 期
Tislelizumab Plus Lenvatinib in Stage III-IV RCCAdvanced Kidney CancerNCT05485883Tianjin Medical University Second Hospital20